The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.